These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 981321)

  • 41. Kantamaneni BD, Curzon G:Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSF.
    Godwin-Austen RB
    J Neurol Neurosurg Psychiatry; 1971 Jun; 34(3):219-23. PubMed ID: 5571307
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biochemical aspects of Huntington's chorea.
    Caraceni T; Calderini G; Consolazione A; Riva E; Algeri S; Girotti F; Spreafico R; Branciforti A; Dall'olio A; Morselli PL
    J Neurol Neurosurg Psychiatry; 1977 Jun; 40(6):581-7. PubMed ID: 143508
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients.
    Garver DL; Bissette G; Yao JK; Nemeroff CB
    Am J Psychiatry; 1991 Apr; 148(4):484-8. PubMed ID: 2006695
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 5-HIAA and HVA in cerebrospinal fluid during delirium acutum.
    Johansson B; Roos BE; Wålinder J
    N Engl J Med; 1972 May; 286(21):1160-1. PubMed ID: 5019651
    [No Abstract]   [Full Text] [Related]  

  • 45. The relationship between clinical and biochemical changes following neuroleptic treatment in schizophrenia.
    Cooper SJ; Leahey W; Liddle J; King DJ
    Schizophr Res; 1990; 3(4):261-7. PubMed ID: 1703780
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High doses of haloperidol in schizophrenia. A clinical, biochemical, and pharmacokinetic study.
    Zarifian E; Scatton B; Bianchetti G; Cuche H; Loo H; Morselli PL
    Arch Gen Psychiatry; 1982 Feb; 39(2):212-5. PubMed ID: 7065833
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cinnarizine-induced parkinsonism in primates.
    García Ruiz PJ; Mena MA; Peñafiel N; De Yébenes JG
    Clin Neuropharmacol; 1992 Apr; 15(2):152-4. PubMed ID: 1375537
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mass fragmentometric determination of homovanillic acid in lumbar cerebrospinal fluid of schizophrenic patients during treatment with antipsychotic drugs.
    Sedvall G; Fyrö B; Nybäck H; Wiesel FA; Wode-Helgodt B
    J Psychiatr Res; 1974; 11():75-80. PubMed ID: 4461807
    [No Abstract]   [Full Text] [Related]  

  • 49. "Tolerance" to neuroleptic-induced CSF HVA rise in schizophrenic patients in relation to clinical response.
    Joseph MH; Waddington JL
    Psychiatry Res; 1982 Aug; 7(1):133. PubMed ID: 6127745
    [No Abstract]   [Full Text] [Related]  

  • 50. Importance of dopamine metabolism for clinical effects and side effects of neuroleptics.
    Van Praag HM; Korf J
    Am J Psychiatry; 1976 Oct; 133(10):1171-7. PubMed ID: 970488
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationships between clinical and biochemical effects of melperone and thiothixene in psychotic women.
    Bjerkenstedt L; Gullberg B; Härnryd C; Sedvall G
    Arch Psychiatr Nervenkr (1970); 1979; 227(3):181-92. PubMed ID: 94992
    [No Abstract]   [Full Text] [Related]  

  • 52. Neuroleptic malignant syndrome: successful treatment with bromocriptine.
    Verhoeven WM; Elderson A; Westenberg HG
    Biol Psychiatry; 1985 Jun; 20(6):680-4. PubMed ID: 3995115
    [No Abstract]   [Full Text] [Related]  

  • 53. Effects of debrisoquin on CSF and plasma HVA concentrations in man.
    Maas JW; Contreras SA; Bowden CL; Weintraub SE
    Life Sci; 1985 Jun; 36(22):2163-70. PubMed ID: 3999921
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment and prognosis of hemiballismus.
    Klawans HL; Moses H; Nausieda PA; Bergen D; Weiner WJ
    N Engl J Med; 1976 Dec; 295(24):1348-50. PubMed ID: 980081
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CSF GABA in psychotic disorders.
    Bowers MB; Gold BI; Roth RH
    Psychopharmacology (Berl); 1980; 70(3):279-82. PubMed ID: 6777800
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol.
    Moleman P; Janzen G; von Bargen BA; Kappers EJ; Pepplinkhuizen L; Schmitz PI
    Am J Psychiatry; 1986 Feb; 143(2):232-4. PubMed ID: 3946663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metoclopramide-induced parkinsonism.
    Yamamoto M; Ujike H; Ogawa N
    Clin Neuropharmacol; 1987 Jun; 10(3):287-9. PubMed ID: 2457440
    [No Abstract]   [Full Text] [Related]  

  • 58. Regional changes of cerebral blood flow during haloperidol therapy in patients with paranoid symptoms.
    Nilsson A; Risberg J; Johanson M; Gustafson L
    Acta Neurol Scand Suppl; 1977; 64():478-9. PubMed ID: 268882
    [No Abstract]   [Full Text] [Related]  

  • 59. Biochemical research into psychosis.
    van Praag HM; Korf J
    Acta Psychiatr Scand; 1975 May; 51(4):268-84. PubMed ID: 238363
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and pharmacological effects of monoamine precursors or haloperidol in chronic schizophrenia.
    Persson T; Roos BE
    Nature; 1968 Mar; 217(5131):854. PubMed ID: 5300360
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.